股本结构
单位：万股
| 公告日期 | 2024-05-14 | 2024-04-30 | 2023-11-09 | 2023-08-10 | 2023-05-15 | 2023-03-30 |
|---|---|---|---|---|---|---|
| 证券总股本 | 543.02 | 543.02 | 373.67 | 373.67 | 373.16 | 373.16 |
| 普通股本 | 543.02 | 543.02 | 373.67 | 373.67 | 373.16 | 373.16 |
| 优先股 | 5.62 | 未披露 | 5.62 | 未披露 | 5.62 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2024-03-31 | 2024-03-13 | 2023-09-30 | 2023-08-10 | 2023-03-31 | 2023-03-28 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2024-05-14 | 543.02 | 5.62 |
更多>>
From December 31, 2023 to March 31, 2024
Issuance of common stock and pre-funded warrants, net
Vesting of restricted stock units
|
2024-03-31 |
| 2024-04-30 | 543.02 | 未披露 | 定期报告 | 2024-03-13 |
| 2023-11-09 | 373.67 | 5.62 |
更多>>
From June 30, 2023 to September 30, 2023
Vesting of restricted stock units
|
2023-09-30 |
| 2023-08-10 | 373.67 | 未披露 | 定期报告 | 2023-08-10 |
| 2023-05-15 | 373.16 | 5.62 |
更多>>
From December 31, 2022 to March 31, 2023
Issuance of common stock, net
Issuance of common stock pursuant to at-the-market stock sales, net
|
2023-03-31 |
| 2023-03-30 | 373.16 | 未披露 | 定期报告 | 2023-03-28 |
| 2023-02-24 | 369.99 | 未披露 |
更多>>
Common stock offered 1,050,000 shares by the company
|
2023-02-27 |
| 2023-02-10 | 264.99 | 未披露 |
更多>>
Aprea Therapeutics, Inc. (APRE) will effect a one-for-twenty (1-20) reverse split of its common stock. The reverse stock split will become effective on Monday, February 13, 2023.
|
2023-02-13 |
| 2022-10-26 | 5299.78 | 未披露 | 定期报告 | 2022-10-20 |
| 2022-11-09 | 5223.79 | 12.86 |
更多>>
From June 30, 2022 to September 30, 2022
Conversion of preferred stock to common stock
Issuance of common stock pursuant to at-the-market stock sales, net
|
2022-09-30 |
| 2022-08-12 | 2340.18 | 未披露 |
更多>>
From March 31, 2022 to June 30, 2022
Issuance of preferred stock upon acquisition of Atrin
Issuance of common stock upon acquisition of Atrin
Vesting of restricted stock units
|
2022-06-30 |
| 2022-06-10 | 2339.72 | 未披露 | 定期报告 | 2022-06-09 |
| 2022-03-15 | 2197.43 | 未披露 | 定期报告 | 2022-03-15 |
| 2022-03-15 | 2185.94 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Exercise of stock options
Vesting of restricted stock units
Issuance of common stock pursuant to at-the-market stock sales, net
|
2021-12-31 |
| 2021-11-08 | 2146.51 | 未披露 | 定期报告 | 2021-11-08 |
| 2021-11-08 | 2136.01 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
Exercise of stock options
Vesting of restricted stock units
|
2021-09-30 |
| 2020-08-11 | 2118.68 | 未披露 |
更多>>
From March 31, 2020 to June 30, 2020
Exercise of stock options
|
2020-06-30 |
| 2020-05-15 | 2105.48 | 未披露 | 定期报告 | 2020-05-15 |
| 2020-05-15 | 2105.49 | 未披露 |
更多>>
From December 31, 2019 to March 31, 2020
Exercise of stock options
|
2020-03-31 |
| 2020-03-27 | 2105.48 | 未披露 | 定期报告 | 2020-03-27 |
| 2020-03-27 | 2102.28 | 未披露 |
更多>>
from December 31, 2018 to December 31, 2019
Conversion of preferred stock into common stock
Issuance of Series C convertible preferred stock, net of issuance costs of $53,509
Issuance of common stock
Exercise of stock options
Common stock issued in IPO, net of issuance costs of $10,843,925
|
2019-12-31 |
| 2019-11-14 | 2099.05 | 未披露 | 定期报告 | 2019-11-13 |
| 2019-10-04 | 1987.65 | 未披露 |
更多>>
1.Common stock offered by us 5,666,667 shares
2.The number of shares of our common stock to be outstanding after the completion of this offering is based on 14,209,865 shares outstanding as of June 30, 2019, after giving effect to the Holdco Reorganization which took place on September 20, 2019 and the 1 for 1.6045 split of our common stock which took place on September 26, 2019 and assumes the conversion of our outstanding convertible preferred stock into 13,028,292 shares of common stock immediately prior to the completion of this offering
|
2019-10-03 |
From December 31, 2023 to March 31, 2024
Issuance of common stock and pre-funded warrants, net
Vesting of restricted stock units
From June 30, 2023 to September 30, 2023
Vesting of restricted stock units
From December 31, 2022 to March 31, 2023
Issuance of common stock, net
Issuance of common stock pursuant to at-the-market stock sales, net
Common stock offered 1,050,000 shares by the company
Aprea Therapeutics, Inc. (APRE) will effect a one-for-twenty (1-20) reverse split of its common stock. The reverse stock split will become effective on Monday, February 13, 2023.
From June 30, 2022 to September 30, 2022
Conversion of preferred stock to common stock
Issuance of common stock pursuant to at-the-market stock sales, net
From March 31, 2022 to June 30, 2022
Issuance of preferred stock upon acquisition of Atrin
Issuance of common stock upon acquisition of Atrin
Vesting of restricted stock units
From December 31, 2020 to December 31, 2021
Exercise of stock options
Vesting of restricted stock units
Issuance of common stock pursuant to at-the-market stock sales, net
From June 30, 2021 to September 30, 2021
Exercise of stock options
Vesting of restricted stock units
From March 31, 2020 to June 30, 2020
Exercise of stock options
From December 31, 2019 to March 31, 2020
Exercise of stock options
from December 31, 2018 to December 31, 2019
Conversion of preferred stock into common stock
Issuance of Series C convertible preferred stock, net of issuance costs of $53,509
Issuance of common stock
Exercise of stock options
Common stock issued in IPO, net of issuance costs of $10,843,925
1.Common stock offered by us 5,666,667 shares
2.The number of shares of our common stock to be outstanding after the completion of this offering is based on 14,209,865 shares outstanding as of June 30, 2019, after giving effect to the Holdco Reorganization which took place on September 20, 2019 and the 1 for 1.6045 split of our common stock which took place on September 26, 2019 and assumes the conversion of our outstanding convertible preferred stock into 13,028,292 shares of common stock immediately prior to the completion of this offering